Limits...
Diagnostic and prognostic value of a disintegrin and metalloproteinase-17 in patients with gliomas.

Wu B, Sha L, Wang Y, Xu W, Yu Y, Feng F, Sun C, Xia L - Oncol Lett (2014)

Bottom Line: A disintegrin and metalloproteinase-17 (ADAM17) has been shown to regulate numerous proteins involved in the cell cycle, as well as tumor oncogenes.The results showed that ADAM17 was upregulated in the high-grade glioma tissues compared with that in the low-grade and normal brain tissues of the glioma patients, and that the level increased with ascending World Health Organization tumor grade (P<0.05).Furthermore, the survival rate of the patients with ADAM17-positive tumors was lower compared with the patients with ADAM17-negative tumors.

View Article: PubMed Central - PubMed

Affiliation: Department of Neurosurgery, Zhejiang Cancer Hospital, Hangzhou, Zhejiang 310022, P.R. China.

ABSTRACT
A disintegrin and metalloproteinase-17 (ADAM17) has been shown to regulate numerous proteins involved in the cell cycle, as well as tumor oncogenes. The expression pattern of ADAM17 in glioma patients, however, is unclear. In the present study, the expression pattern and prognostic significance of ADAM17 was investigated in patients with glioma. A total of 60 glioma specimens and eight normal control samples were obtained. Immunohistochemical and western blot analyses were used to examine the expression of ADAM17. In addition, the association of ADAM17 expression with the clinicopathological parameters and the survival rates of the glioma patients was analyzed. The results showed that ADAM17 was upregulated in the high-grade glioma tissues compared with that in the low-grade and normal brain tissues of the glioma patients, and that the level increased with ascending World Health Organization tumor grade (P<0.05). Furthermore, the survival rate of the patients with ADAM17-positive tumors was lower compared with the patients with ADAM17-negative tumors. These results indicated that the overexpression of ADAM17 was correlated with a high tumor grade and a poor prognosis in patients with glioma. ADAM17 may have an important oncogenic function in glioma progression, and is a potential diagnostic and therapeutic target.

No MeSH data available.


Related in: MedlinePlus

Immunohistochemical analysis of ADAM17 immunoreactivity in normal brain and glioma tissues (magnification, ×400). Gliomas with high grades exhibited stronger ADAM17 protein expression compared with gliomas with lower grades and the normal brain tissues (P<0.05). ADAM17, a disintegrin and metalloproteinase-17.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4214486&req=5

f2-ol-08-06-2616: Immunohistochemical analysis of ADAM17 immunoreactivity in normal brain and glioma tissues (magnification, ×400). Gliomas with high grades exhibited stronger ADAM17 protein expression compared with gliomas with lower grades and the normal brain tissues (P<0.05). ADAM17, a disintegrin and metalloproteinase-17.

Mentions: The ADAM17 protein expression in the eight control and 60 glioma cases was detected by IHC staining. The results showed that ADAM17 was predominantly located in the cytoplasm and was rarely expressed in the nucleus (Fig. 2). The positive rate of ADAM17 expression in the glioma patients of all grades was 88.33%, whereas it was only 37.5% in the control group. The strong positive expression rate of ADAM17 in the control, low-grade glioma and high-grade glioma groups was 0, 0.4 and 51.43%, respectively. The negative expression rate of ADAM17 in the control group was 62.5%, whereas it was only 0.29% in the high-grade glioma group (Table I). These results indicated that ADAM17 expression was significantly higher in the high grade glioma group (WHO III–IV) compared with the low-grade glioma (WHO I–II) and control groups.


Diagnostic and prognostic value of a disintegrin and metalloproteinase-17 in patients with gliomas.

Wu B, Sha L, Wang Y, Xu W, Yu Y, Feng F, Sun C, Xia L - Oncol Lett (2014)

Immunohistochemical analysis of ADAM17 immunoreactivity in normal brain and glioma tissues (magnification, ×400). Gliomas with high grades exhibited stronger ADAM17 protein expression compared with gliomas with lower grades and the normal brain tissues (P<0.05). ADAM17, a disintegrin and metalloproteinase-17.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4214486&req=5

f2-ol-08-06-2616: Immunohistochemical analysis of ADAM17 immunoreactivity in normal brain and glioma tissues (magnification, ×400). Gliomas with high grades exhibited stronger ADAM17 protein expression compared with gliomas with lower grades and the normal brain tissues (P<0.05). ADAM17, a disintegrin and metalloproteinase-17.
Mentions: The ADAM17 protein expression in the eight control and 60 glioma cases was detected by IHC staining. The results showed that ADAM17 was predominantly located in the cytoplasm and was rarely expressed in the nucleus (Fig. 2). The positive rate of ADAM17 expression in the glioma patients of all grades was 88.33%, whereas it was only 37.5% in the control group. The strong positive expression rate of ADAM17 in the control, low-grade glioma and high-grade glioma groups was 0, 0.4 and 51.43%, respectively. The negative expression rate of ADAM17 in the control group was 62.5%, whereas it was only 0.29% in the high-grade glioma group (Table I). These results indicated that ADAM17 expression was significantly higher in the high grade glioma group (WHO III–IV) compared with the low-grade glioma (WHO I–II) and control groups.

Bottom Line: A disintegrin and metalloproteinase-17 (ADAM17) has been shown to regulate numerous proteins involved in the cell cycle, as well as tumor oncogenes.The results showed that ADAM17 was upregulated in the high-grade glioma tissues compared with that in the low-grade and normal brain tissues of the glioma patients, and that the level increased with ascending World Health Organization tumor grade (P<0.05).Furthermore, the survival rate of the patients with ADAM17-positive tumors was lower compared with the patients with ADAM17-negative tumors.

View Article: PubMed Central - PubMed

Affiliation: Department of Neurosurgery, Zhejiang Cancer Hospital, Hangzhou, Zhejiang 310022, P.R. China.

ABSTRACT
A disintegrin and metalloproteinase-17 (ADAM17) has been shown to regulate numerous proteins involved in the cell cycle, as well as tumor oncogenes. The expression pattern of ADAM17 in glioma patients, however, is unclear. In the present study, the expression pattern and prognostic significance of ADAM17 was investigated in patients with glioma. A total of 60 glioma specimens and eight normal control samples were obtained. Immunohistochemical and western blot analyses were used to examine the expression of ADAM17. In addition, the association of ADAM17 expression with the clinicopathological parameters and the survival rates of the glioma patients was analyzed. The results showed that ADAM17 was upregulated in the high-grade glioma tissues compared with that in the low-grade and normal brain tissues of the glioma patients, and that the level increased with ascending World Health Organization tumor grade (P<0.05). Furthermore, the survival rate of the patients with ADAM17-positive tumors was lower compared with the patients with ADAM17-negative tumors. These results indicated that the overexpression of ADAM17 was correlated with a high tumor grade and a poor prognosis in patients with glioma. ADAM17 may have an important oncogenic function in glioma progression, and is a potential diagnostic and therapeutic target.

No MeSH data available.


Related in: MedlinePlus